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SESSION INFORMATION
Cardiovascular 
Disease in a Large Incident Cohort of Early In ammatory Arthritis
Background/Purpose:  
Rheumatoid Arthritis (RA) is associated with an increased risk of 
cardiovascular disease (CVD). The aim of this study is to determine the 
incidence and predictors of CVD in Early In ammatory Arthritis (EIA) from the 
Canadian early arthritis cohort (CATCH).
Methods: CATCH 
is a multicentre, prospective inception cohort of patients with EIA. Cardiovascular 
disease (CVD) was de ned as an acute coronary syndrome, percutaneous or 
surgical intervention for coronary artery disease, stroke, transient ischemic 
attack, peripheral vascular disease requiring surgical intervention or death 
secondary to CVD. Pre-existing diagnoses of CVD, risk factors and medications 
for CVD were collected at baseline by physician. Incident CVD events and 
cardiac medications after study enrollment were self-reported by patients. Stepwise 
logistic regression was used to identify predictors for CVD. 
Results:  
2652 patients were enrolled in the study with a mean follow-up of 3.4 (SD 2.1) 
years. At baseline, 180 (7%) had pre-existing CVD. During the course of 
follow-up there were 62 new CVD events in 57 subjects. There were a total of 6 deaths (1 secondary 
to CVD). The incidence rate of CVD for years 1, 2, 3, 4 and 5 of the study, respectively 
were: 2.3, 4.4, 15.4, 10.4, 10.8 per 1000 person-years. Patients with new CVD 
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events were older, more likely male and have higher rates of traditional CVD 
risk factors (Table 1). Arthritis-related factors were not signi cantly 
associated with the risk of CVD. Independent predictors of CVD were male gender 
(OR 1.8 (95% CI: 1.0-3.0), dyslipidemia (OR 1.8 (95% CI: 1.1-3.2)), hypertension 
(OR 2.7 (95% CI: 1.6-4.6)) and the use of non-steroidal anti-in ammatories (NSAIDs) 
(OR 3.2 (95% CI: 1.8-5.6). Less than 25% of subjects with a CVD diagnosis 
reported taking aspirin or cholesterol-lowering drugs during the follow-up 
period.
Conclusion:   
The rate of CVD events in patients 
with EIA was higher later in the disease course.  CVD appears to be 
under-treated and is independently associated with traditional CVD risk factors 
and the use of NSAIDs. 
Table 1: Baseline characteristics of EIA patients with a new CVD event 
versus those that did not have a new CVD event
  New CVD No New CVD p-value
N 57 2595  
Age, mean years (SD) 61.2 (13.6) 53.3 (14.8) <0.0001
Female 31 (54) 1874 (72) 0.0037
Symptom Duration,
days mean (SD)
234.8 (129.0) 184.7 (115.9) <0.0001
Ever Smoker 41 (72) 1441 (56) 0.0136
RA criteria 52 (93) 2218 (86) 0.1314
Seropositive 29 (76) 1150 (67) 0.2307
DAS28, mean (SD) 4.87 (1.50) 4.66 (1.45) 0.3017
HAQ, mean (SD) 0.86 (0.67) 0.88 (0.69) 0.8130
Erosions 15 (31) 480 (23) 0.2375
CRP, mean (SD) (mg/L) 14.8 (17.9) 13.9 (17.9) 0.7004
ESR, mean (SD) 26.5 (22.8) 26.4 (22.7) 0.9820
Diabetes 9 (16) 210 (8) 0.037






Dyslipidemia 19 (33) 426 (16) 0.0007
DMARDs 50 (88) 2128 (82) 0.2800      
Methotrexate 39 (68) 1712 (65) 0.5458
Biologics 3 (5) 52 (2) 0.1192
Corticosteroids 32 (56) 1271 (49) 0.2674
NSAID 14 (25) 234 (9) <0.0001
De ned as past or present smoker
Meets ACR 1987 RA criteria or ACR/EULAR 2010 RA criteria
N=1752 with available data on antibodies; seropositive de ned as Rheumatoid Factor or Anti-
Citrullinated Peptide Antibody positive
N= 2103 with available data on presence of erosions on plain radiographs
EIA= Early In ammatory Arthritis, DAS28= Disease Activity Score 28, HAQ= Health Assessment
Questionnaire Score, ESR= Erythrocyte Sedimentation Rate, CRP= C-Reactive Protein, ,
ACR=American College of Rheumatology, RA= Rheumatoid Arthritis, EULAR= European League
Against Rheumatism, DMARDs= Disease Modifying Anti-Rheumatic Drugs, NSAID= Non-Steroidal
Anti-In ammatories
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